

RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

Sep 13, 2008

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/rad001-combined-sandostatin-lar-depot-and-monotherapy-controls-growth-rare-pancreatic-neuroendocrine-tumors-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/rad001-combined-sandostatin-lar-depot-and-monotherapy-controls-growth-rare-pancreatic-neuroendocrine-tumors-0>